In this rebroadcasted episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Mansoor Raza Mirza to discuss the RUBY Trial. Dr. Mirza is a highly qualified medical oncologist with expertise in Medical and Radiation Oncology, holding multiple degrees and licenses in these fields. He currently serves as the Chief Oncologist at the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark, and holds the position of Medical Director of the Nordic Society of Gynaecologic Oncology-Clinical Trial Unit (NSGO-CTU). Dr. Mirza is actively involved in numerous medical societies, clinical research, and international trial collaborations, and has contributed significantly to the development of clinical protocols and guidelines for the management of various cancers.
- The phase 3 RUBY trial evaluated the combination of dostarlimab, a PD-1 inhibitor, with carboplatin and paclitaxel versus placebo, carboplatin, and paclitaxel in patients with primary advanced or recurrent endometrial cancer.
- Interim analysis of the trial showed improved progression-free survival (PFS) in the population with mismatch repair–deficient (dMMR) endometrial cancer. The 2-year PFS rate in the dMMR population was 61.4%, with a hazard ratio (HR) of 0.28. Some patients treated with the dostarlimab combination showed no disease progression after 12 months of follow-up, suggesting potential cure.
- The dostarlimab combination also demonstrated a trend toward overall survival (OS) improvement in both the dMMR and mismatch repair–proficient (pMMR) subgroups. However, the OS data are still immature, and further follow-up is needed to determine the efficacy of the treatment.